

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Maniar Manoj</u>  (Last) (First) (Middle) C/O ONCONOVA THERAPEUTICS, INC. 375 PHEASANT RUN  (Street) NEWTOWN PA 18940  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 04/27/2015	3. Issuer Name and Ticker or Trading Symbol <u>Onconova Therapeutics, Inc. [ ONTX ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) SVP - Product Development	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to buy)	08/01/2007	08/01/2017	Common Stock	11,252	6	D	
Stock Option (right to buy)	03/17/2010	03/17/2020	Common Stock	37,509	5.76	D	
Stock Option (right to buy)	03/17/2010	03/17/2020	Common Stock	18,754	5.76	D	
Stock Option (right to buy)	12/10/2010	12/10/2020	Common Stock	7,501	6.13	D	
Stock Option (right to buy)	12/10/2010	12/10/2020	Common Stock	18,754	6.13	D	
Stock Option (right to buy)	12/05/2011	12/05/2021	Common Stock	3,780	6.13	D	
Stock Option (right to buy)	(1)	12/18/2022	Common Stock	30,007	13.28	D	
Stock Option (right to buy)	(2)	07/25/2023	Common Stock	5,000	15	D	
Stock Option (right to buy)	(3)	12/20/2023	Common Stock	40,000	13.48	D	
Stock Option (right to buy)	(4)	12/18/2024	Common Stock	60,000	3.98	D	
Stock Option (right to buy)	(5)	04/16/2025	Common Stock	40,000	2.32	D	

**Explanation of Responses:**

- This option, representing a right to buy, vests over 4 years, with 25% vesting on December 18,2013 and 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the issuer.
- This option, representing a right to buy, vests over 4 years, with 25% vesting on July 25,2014 and 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the issuer.
- This option, representing a right to buy, vests in 48 equal monthly installments over 4 years. The first shares vest one month after the date of grant, which was December 20, 2013.
- This option, representing a right to buy, vests in 48 equal monthly installments over 4 years. The first shares vest one month after the date of grant, which was December 18, 2014.
- This option, representing a right to buy, vests in 48 equal monthly installments over 4 years. The first shares vest one month after the date of grant, which was April 16, 2015.

**Remarks:**

Exhibit 24 attached.

/s/ Ajay Bansal, as attorney in fact 05/21/2015

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

Know all by these presents, that the undersigned hereby makes, constitutes and appoints Ramesh Kumar, Ph.D. and Ajay Bansal as the undersigned's true and lawful attorney-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to:

(1) prepare, execute, acknowledge, deliver and file Forms 3, 4, and 5 (as applicable, including any amendments thereto) with respect to the securities of Onconova Therapeutics, Inc., a Delaware corporation (the "Company"), with the United States Securities and Exchange Commission, any national securities exchanges and the Company, as considered necessary or advisable under Section 16(a) of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from time to time (the "Exchange Act");

(2) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the Company's securities from any third party, including but not limited to brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such third party to release any such information to the undersigned and approves and ratifies any such release of information to the undersigned; and

(3) perform any and all other acts which in the discretion of such attorney-in-fact are necessary or desirable for and on behalf of the undersigned in connection with the foregoing.

The undersigned acknowledges that:

(1) this Limited Power of Attorney authorizes, but does not require, such attorney-in-fact to act in his discretion on information provided to such attorney-in-fact without independent verification of such information;

(2) any documents prepared and/or executed by such attorney-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney will be in such form and will contain such information and disclosure as such attorney-in-fact, in his discretion, deems necessary or desirable;

(3) neither the Company nor such attorney-in-fact assumes (i) any liability for the undersigned's responsibility to comply with the requirements of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and

(4) this Limited Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under the Exchange Act, including without limitation the reporting requirements under Section 16 of the Exchange Act.

The undersigned hereby gives and grants the foregoing attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing matters as fully to all intents and purposes as the undersigned might or could do if present, hereby ratifying all that such attorney-in-fact of, for and on behalf of the undersigned, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney.

This Limited Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to such attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney to be executed as of this 16th day of January, 2015.

\_/s/ MANOJ MANIAR  
Name: Manoj Maniar